American Society of Hirudotherapy

Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why?.

Research article published in European heart journal (2013)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewClinical TrialsLip · European heart journal, 2013

Abstract

Decision making with regard to thromboprophylaxis should be based upon the absolute risks of stroke/thromboembolism and bleeding and the net clinical benefit for a given patient. As a consequence, a crucial part of atrial fibrillation (AF) management requires the appropriate use of thromboprophylaxis, and the assessment of stroke as well as bleeding risk can help inform management decisions by clinicians. The objective of this review article is to provide an overview of stroke and bleeding risk assessment in AF. There would be particular emphasis on when, how, and why to use these risk stratification schemes, with a specific focus on the CHADS2 [congestive heart failure, hypertension, age, diabetes, stroke (doubled)], CHA2DS2-VASc [congestive heart failure or left ventricular dysfunction, hypertension, age ≥ 75 (doubled), diabetes, stroke (doubled)-vascular disease, age 65-74 and sex category (female)], and HAS-BLED [hypertension (i.e. uncontrolled blood pressure), abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR (if on warfarin), elderly (e.g. age >65, frail condition), drugs (e.g. aspirin, NSAIDs)/alcohol concomitantly] risk scores.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAgedAnticoagulantsAspirinAtrial FibrillationBiomarkersEchocardiographyFemaleFibrinolytic AgentsHemorrhageHumansMalePractice Guidelines as Topic

Summary

Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why?.

Why This Matters for Hirudotherapy

This review article provides an overview of stroke and bleeding risk assessment in atrial fibrillation, focusing on the CHADS2, CHA2DS2-VASc, and HAS-BLED risk stratification schemes to guide thromboprophylaxis decisions. The abstract addresses anticoagulant decision-making frameworks but makes no reference to leeches, hirudotherapy, hirudin, or any leech-derived substance. There is no defensible leech-related relevance; the content is entirely within the domain of oral anticoagulant risk stratification for cardiac patients.

Citation

Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why?.

Lip · European heart journal, 2013

Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.